Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapiesSumit Kar, Mallika Singh, Yongxian Zhuang et al.|Cancer Research|2025Cited by 9
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination StrategiesIda Aronchik, Mallika Singh, Lo Lai et al.|Molecular Cancer Therapeutics|2025Cited by 1